George Scangos, Vir CEO (David Paul Morris/Bloomberg via Getty Images)
Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for combination trial
In December, Gilead closed out a year-long spending spree on cancer drugs by closing a deal much closer to their roots: a $1.7 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
